RT Journal Article
SR Electronic
T1 Accounting for assay performance when estimating the temporal dynamics in SARS-CoV-2 seroprevalence in the U.S
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.09.13.22279702
DO 10.1101/2022.09.13.22279702
A1 Bernardo García-Carreras
A1 Matt D. T. Hitchings
A1 Michael A. Johansson
A1 Matthew Biggerstaff
A1 Rachel B. Slayton
A1 Jessica M. Healy
A1 Justin Lessler
A1 Talia Quandelacy
A1 Henrik Salje
A1 Angkana T. Huang
A1 Derek A. T. Cummings
YR 2022
UL http://medrxiv.org/content/early/2022/09/18/2022.09.13.22279702.abstract
AB Estimating the incidence of SARS-CoV-2 infection is central to understanding the state of the pandemic. Seroprevalence studies are often used to assess cumulative infections as they can identify asymptomatic infection. Since July 2020, commercial laboratories have conducted nationwide serosurveys for the U.S. CDC. They employed three assays, with different sensitivities and specificities, potentially introducing biases in seroprevalence estimates. Using mechanistic models, we show that accounting for assays explains some of the observed state-to-state variation in seroprevalence, and when integrating case and death surveillance data, we show that when using the Abbott assay, estimates of proportions infected can differ substantially from seroprevalence estimates. We also found that states with higher proportions infected (before or after vaccination) had lower vaccination coverages, a pattern corroborated using a separate dataset. Finally, to understand vaccination rates relative to the increase in cases, we estimated the proportions of the population that received a vaccine prior to infection.Competing Interest StatementB.G.-C., M.D.T.H., and D.A.T.C. report a contract from Merck (to the University of Florida) for research unrelated to this manuscriptFunding StatementThis study was funded by a grant from the National Science Foundation, award number 2223843 (B.G.C., M.D.T.H., and D.A.T.C.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used and produced will be available online.